SCHEMBL30139764

SCHEMBL30139764

CC(C)[C@H]1c2ncc(Cl)cc2C(C)N1C(=O)OC(C)(C)C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.34
KCNK3 O14649 3/20 0.34
KCNK9 Q9NPC2 3/20 0.34
CACNA1G O43497 1/20 0.34
CACNA1H O95180 1/20 0.34
CACNA1I Q9P0X4 1/20 0.34
RORC P51449 1/20 0.33
GPR119 Q8TDV5 1/20 0.32
FNTA P49354 4/20 0.32
FNTB P49356 4/20 0.32
RET P07949 1/20 0.31
PSEN1 P49768 1/20 0.31
PSEN2 P49810 1/20 0.31
APH1B Q8WW43 1/20 0.31
NCSTN Q92542 1/20 0.31
APH1A Q96BI3 1/20 0.31
PSENEN Q9NZ42 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP3A5 P20815 1/20 0.31
STS P08842 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16968605 1.00 TRPA1 (0.34) TRPA1KCNK3KCNK9CACNA1GCACNA1H
SCHEMBL16968545 0.85 RORC (0.34) RORCGPR119
SCHEMBL16972926 0.83 CACNA1G (0.39) CACNA1GCACNA1HCACNA1I
SCHEMBL17911689 0.83 CACNA1G (0.39) CACNA1GCACNA1HCACNA1I
SCHEMBL23701497 0.80 KMT2A (0.36) TRPA1KCNK3KCNK9CACNA1GCACNA1H
SCHEMBL16968531 0.74 MEN1 (0.42) RORCGPR119FNTAFNTB
SCHEMBL30139745 0.74 MEN1 (0.42) RORCGPR119FNTAFNTB
SCHEMBL20504306 0.73 GHSR (0.40) RORCGPR119FNTAFNTB
SCHEMBL20504307 0.73 GHSR (0.40) RORCGPR119FNTAFNTB
SCHEMBL30139762 0.72 RORC (0.55) RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11535614-B2 Dihydropyrrolopyridine inhibitors of ROR-gamma VITAE PHARMACEUTICALS, LLC (US) 2022-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11535614-B2 Dihydropyrrolopyridine inhibitors of ROR-gamma RORC, RORB, RORA TRPA1 609/4885KCNK3 1027/4885KCNK9 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.